Summary
The treatment:in vivo with anti-tumour drugs can induce an antigenic alteration of L1210 leukemia resulting in the rejection of an inoculum of 10×106 viable cells in syngeneic mice. As drug-induced antigens appeared in excess of any pre-existing tumour-associated transplantation antigens (TATA), viable altered cells have been used to sensitize syngeneic animals. Experiments showed that viable altered cells elicited stronger anti-TATA reaction than X-inactivated parental cells, as measured by host survival to a challenge of L1210 leukemia. TATA immunogenicity of parental cells has been preminent, in the strain of animals used, to determine the sensitizing effectiveness of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) cells. Host protection to an inoculum of parental tumours has been more proficient with the DTIC subline derived from highly immunogenic L1210Ha cells than from poorly immunogenic L1210Cr cells. Immunoprophylactic inocula, proper chemotherapeutic treatments and adoptive transfer of immune lymphocytes used in combination exerted a synergic host protection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Attia M. A., Weiss D. W.: Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus—Cancer Res.26, 1787, 1966.
Bonmassar E., Bonmassar A., Vadlamudi S., Goldin A.: Immunological alteration of leukemic cellsin vivo after treatment with an anti-tumor drug—Proc. nat. Acad. Sci. (Wash.)66, 1089, 1970.
Boone C. W., Paranjpe M., Orme T., Gillette R.: Virus-augmented tumor transplantation antigens: evidence for a helper antigen mechanism—Jnt. J. Cancer13, 543, 1974.
Bubenik J., Koldovsky P.: Factors influencing the induction of enhancement and resistance to methylcholanthrene-induced tumors in a syngeneic system—Folia biol. (Praha)11, 258, 1965.
Cerottini J. C., Engers H. D., MacDonald H. R., Brunner K. T.: Generation of cytotoxic T-lymphocytes ‘in vitro’ response of normal and immune mouse spleen cells in mixed lymphocyte cultures—J. exp. Med.140, 703, 1974.
Colman N. S., Eng B., Slater L. M., Wallerstein H.: Antigenic changes associated with resistance to methotrexate and 6-mercaptopurine in L1210 ascites lymphoma—J. nat. Cancer Inst.55, 207, 1975.
Gielis S., Smith K. A.: Long-term cultures of tumor-specific cytotoxic T cells—Nature (Lond.)268, 154, 1977.
Glynn J. P., Humphrey S. R., Trivers G., Bianco A. R., Goldin A.: Studies on immunity to leukemia L1210 in mice—Cancer Res.23, 1008, 1963.
Martin J. W., Wünderlich J. R., Fletcher F., Inman J. K.: Enhanced immunogenicity of chemically coated syngeneic tumor cells—Proc. nat. Acad. Sci. (Wash.)68, 469, 1971.
Mihich E.: Synergism between chemotherapy and immunity in the treatment of experimental tumors—In:Spitzy K. H., Haschek H. (Eds). Proc. V Int. Congr. on Chemotherapy, Wiener Medizinische Akademie, Vienna, 1967; vol. 3, p. 327.
Mihich E.: Modification of tumor regression by immunologic means—Cancer Res.29, 2345, 1969.
Nicolin A., Bini A., Coronetti E., Goldin A.: Cellular immune response to a drug-treated L5178Y lymphoma subline—Nature (Lond.)251, 654, 1974.
Nicolin A., Bini A., Di Padova F., Goldin A.: Immunologic cross-reactivity of antigen(s) induced by a drug treatment in two leukemic sublines—J. Immunol.116, 5, 1976.
Nicolin A., Canti G., Goldin A.: Adoptive immunotherapy in Balb/cxDBA/2CrF. mice bearing an immunogenic subline of L1210 leukemia—Cancer Res.34, 3044, 1974.
Nicolin A., Franco P., Testorelli C., Goldin A.: Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells—Cancer Res.36, 222, 1976.
Nicolin A., Spreafico F., Bonmassar E., Goldin A.: Antigenic changes of l5178Y lymphoma after treatment with 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide ‘in vivo’—J. nat. Cancer Inst.56, 89, 1976.
Nicolin A., Vadlamudi S., Goldin A.: Antigenicity of L1210 leukemic sublines induced by drugs—Cancer Res.32, 653, 1972.
Nicolin A., Vadlamudi S., Goldin A.: Increased immunogenicity of murine lymphatic tumors by pyrazole-4-carboxamide 3 (or 5) amino (NSC-1402, PCA)—Cancer Chemother. Abstr.57, 3, 1973.
Schmid F. A., Hutchison D. J.: Collateral sensitivity of resistant lines of mouse leukemias L1210 and L5178Y—Cancer Res.32, 808, 1972.
Weiss L.: Neuraminidase, sialic acids and cell interactions—J. nat. Cancer Inst.50, 1, 1973.
Author information
Authors and Affiliations
Additional information
Research supported in part by contract no. 75.01454.04 from theConsiglio Nazionale delle Ricerche (CNR), Roma, Italy.
Rights and permissions
About this article
Cite this article
Boerio, D., Cavalli, M., Marelli, O. et al. Vaccination of leukemic mice with viable drug-altered leukemic cells. La Ricerca Clin. Lab. 8, 127–133 (1978). https://doi.org/10.1007/BF02904984
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02904984